Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2008 Apr 10;13(3):535–546. doi: 10.1111/j.1582-4934.2008.00341.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2009 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

PMC Copyright notice

Angiogenic effect of AG-30 in mouse ischaemic hind limb model. (A) Slow release profile of ¹²⁵I-labelled AG-30 with/without gelatin microspheres or ¹²⁵I-labelled gelatin at 3, 7, 14 and 21 day. (B) Evaluation of angiogenic effect by measuring mouse hind limb blood flow at pre-treatment (pre), 1, 2, 3 and 4 week. Ischaemic hind limb mouse were treated with gelatin/AG-30 (500 μg or 100 μg), gelatin/control peptide (500 μg), only AG-30 (500 μg) or PBS. Upper panel shows representative pictures of LDI images of hind limb blood flow at pre-, 2 and 4 weeks after treatment. *P < 0.05 versus control peptide gelatin. (C) Evaluation of capillary density of the AG-30-treated ischaemic hind limb. Upper panel shows representative photomicrographs (×400) of tissue immunostained with anti-CD31 antibody. Lower panel shows number of capillary per field. *P < 0.05 versus control peptide gelatin. n= 5–8 per group.

Angiogenic effect of AG-30 in mouse ischaemic hind limb model. (A) Slow release profile of ¹²⁵I-labelled AG-30 with/without gelatin microspheres or ¹²⁵I-labelled gelatin at 3, 7, 14 and 21 day. (B) Evaluation of angiogenic effect by measuring mouse hind limb blood flow at pre-treatment (pre), 1, 2, 3 and 4 week. Ischaemic hind limb mouse were treated with gelatin/AG-30 (500 μg or 100 μg), gelatin/control peptide (500 μg), only AG-30 (500 μg) or PBS. Upper panel shows representative pictures of LDI images of hind limb blood flow at pre-, 2 and 4 weeks after treatment. *P < 0.05 versus control peptide gelatin. (C) Evaluation of capillary density of the AG-30-treated ischaemic hind limb. Upper panel shows representative photomicrographs (×400) of tissue immunostained with anti-CD31 antibody. Lower panel shows number of capillary per field. *P < 0.05 versus control peptide gelatin. n= 5–8 per group.